Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. (not Eyepoint, Inc.) on March 2, 2017. The report details a corporate event occurring on the same date involving a strategic partnership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific contractual event rather than financial performance.
Material Changes
On March 2, 2017, pSivida Corp. entered into a funded feasibility study agreement with a leading biopharmaceutical company. The agreement involves:
- Phase One: Formulating the Company's proprietary Durasert sustained release drug technology with the partner's proprietary molecules to assess pre-clinical benefits.
- Phase Two: A potential future stage contingent on Phase One results, involving further pre-clinical work combining Durasert with selected molecules.
Guidance, Outlook, and Risks
Management commentary indicates that the biopharmaceutical partner may elect to proceed to Phase Two pending the results of the initial formulation research. The filing does not disclose specific financial guidance, risk factors, or contingencies beyond the conditional nature of the second phase.
Investor Verification Checklist
- Verify the identity of the "leading biopharmaceutical company" partner.
- Confirm the total funding amount provided under the feasibility study agreement.
- Review the specific timeline and milestones for Phase One research.
- Assess the potential financial impact of a successful Phase Two election.